I’m not entirely sure about the email regarding auditing ClinicalTrials.gov submissions. I have participated with the DIA and others to construct a survey that deals with disclosure operations and policies for both industry and academia. Perhaps this is what you mean? In my experience, I have found that academic medical institutions/academic research organizations lag substantially behind in terms of preparing protocol registrations/results records and generally have not constructed institutional disclosure policies and compliance tracking to minimize risk to the organization. This is the type of work I do (although I choose the term “assess” rather than audit because I am not an accountant and do not do financial risk audits) and I am currently working with both industry and academia to assist them with their disclosure efforts.